Evidence map›Paper›PMID 36226340›Full record

ArticleJournal of genetics2022

Missing apolipoprotein E ε4 allele associated with nonamnestic Alzheimer's disease in a Tunisian population.

Saloua Fray, Afef Achouri-Rassas, Samir Belal, Taieb Messaoud

Abstract read
PubMed
In one paragraph

Article in Journal of genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Saloua FrayDepartment of Neurology, Charles Nicolle Hospital, Tunis, Tunisia. fray_saloua@yahoo.fr.
Afef Achouri-Rassas
Samir Belal
Taieb Messaoud

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we investigate the impact of apolipoprotein E epsilon 4 (APOE ε4) as a major risk factor of Alzheimer's disease (AD), based on the clinical presentation of the disease in our population on the one hand, and comparison of the results with the findings from the literature on the other hand. Our study covered a population of 144 patients versus 90 healthy controls matched with each other in terms of age, gender, age of onset, etc. All patients underwent neurological examination, comprehensive neuropsychological assessment and brain magnetic resonance imaging. Controls were selected based on the neurological examination and the Arabic version of the minimental state examination (MMSE). Patients were classified as probable typical amnestic AD and atypical nonamnestic AD if the patient had logopenic variant primary aphasia, posterior cortical atrophy, behavioural or dysexecutive variants, corticobasal syndrome, nonfluent and semantic variants of primary progressive aphasia associated to biological diagnosis for AB42, Tau and Ptau biomarks in the cerebrospinal fluid. Genotyping was performed using the polymerace chain reaction restriction fragment length polymorphism (PCR-RFLP) method. The study of the allelic frequency of APOE in cases and controls show that APOE ε4 is associated with an increased risk for AD (

Indexed as

Alzheimer DiseaseApolipoprotein E4AllelesApolipoproteins EGene FrequencyGenotypeHumansNeuropsychological TestsApoE protein, humanApolipoprotein E4Apolipoproteins E

Identifiers

PMID36226340

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.